The dengue vaccines market will register positive growth with the overall valuation forecast to reach USD 474.8 million in 2023. Thee demand for dengue vacciness is projected to surge with a projected CAGR of 12.9% by sales in volume (units).
Dengue vaccine development has entered an important stage of its lifecycle - with a host of pharmaceutical giants expected to present the results of their extensive clinical trials initiated in the past decade or half-a-decade. The future availability of various alternatives is likely to break the monopoly of the existing Denvaxia® vaccine.
A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering new vaccine formulations. Majority growth is likely to remain concentrated across the Asia-Pacific region, attributed to maximum dengue fever concentration as well as the presence of reputed regional pharmaceutical giants.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for dengue vaccines. The report tracks the global sales of dengue vaccines in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the healthcare industry in general, and dengue vaccines in particular.
| Attributes | Details |
|---|---|
| Dengue Vaccines Market Value (2022) | USD 422.6 million |
| Dengue Vaccines Market Value (2023) | USD 474.8 million |
| Dengue Vaccines Market Expected Value (2033) | USD 1603.7 million |
| Dengue Vaccines Market Projected CAGR (2023 to 2033) | 12.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The dengue vaccines market was valued at nearly USD 250 million in 2017, with a plethora of pharmaceutical giants investing in R&D funding to initiate large-scale clinical trials. Up until now, the market has experienced only one major breakthrough in terms of vaccine availability, a trend which is expected to be relegated to the past, as companies are expected to publish their finding by 2023-end.
This is expected to result in multiple vaccine candidates in the upcoming decade. Amidst the COVID-19 pandemic, dengue vaccine product has taken a temporary backseat, as prominent manufacturers have dedicated existing production units towards the development of an anti-SARS CoV-2 vaccine, as evidenced by Takeda Pharmaceutical’s ad hoc surrender of its facility at IDT Biologika GmbH to Johnson and Johnson to manufacture single-shot COVID-19 vaccines.
According to FMI’s analysis, the global dengue vaccines market is expected to witness prolific developments in the future, expected to cross USD 1603.7 million by 2033 and register a double digit CAGR during the forecast period. As key pharmaceutical companies conclude their clinical trials, analysts are hopeful of new product launches, thereby widening the growth scope.
According to the World Health Organization, the incidence of dengue has grown dramatically over recent decades. A vast majority of the cases are asymptomatic, mild, or self-managed, and hence the actual number of infections is highly under-reported. One modeling estimate indicates 390 million dengue virus infections per year (95% credible interval 284-528 million), of which 96 million manifest clinically.
Another clinical study has established that nearly 4 billion people are at risk of infection. Despite a risk of infection existing in 129 countries, 70% of the actual burden is concentrated in Asia. Furthermore, the number of reported dengue cases over the past two decades has increased eightfold since the past 20 years, from 505,430 cases in 2000 to over 2.4 million in 2019, with death rates climbing from 960 to 4032.
As of 2020, dengue continues to affect several countries, with the Americas reporting over 3 million cases out of which 25,000 are classified as severe. High incidences were also reported across Bangladesh (101,000), Malaysia (131,000), the Philippines (420,000), and Vietnam (320,000). Hence, major pharmaceutical giants are accelerating the pace of their ongoing clinical trials, as well as initiating new ones so as to capitalize on this opportunity and expand their presence.
Principal Consultant
Amid the dearth of adequate vaccine candidate availability in the market, prominent pharmaceutical manufacturing hubs are leveraging international level partnerships so as to further vaccine research & development. For instance, the Department of Biotechnology in India is directing concerted efforts to strengthen vaccine R&D through its Vaccine Action Program.
As part of this initiative, the Indo-USA Vaccine Action Program (VAP) was initiated in 2017. This is a bilateral program developed by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) within the Department of Health and Human Services, United States, and the Department of Biotechnology (DBT), Ministry of Science and Technology, Government of India, in conjunction with the Human Immunology Project Consortium (HIPC).
India’s market for dengue vaccines is undergoing a critical change with assistance from national expert groups and the aforementioned program. Important stakeholders are gaining awareness about such collaborative initiatives, which are assisting key pharmaceutical corporations achieve significant strides in vaccine development. This is anticipated to bolster growth prospects for the global dengue vaccines market in forthcoming years.
As the global dengue fever incidence burden is largely concentrated across Asian countries, prominent pharmaceutical corporations are expected to find promising revenue streams across countries such as India, Japan, and South East Asia. Takeda Pharmaceuticals, a prominent Japanese multinational pharmaceutical company, has begun its regulatory submissions for the dengue vaccine candidate, TAK-003, in the EU and dengue-endemic countries including Brazil and Indonesia.
On a similar note, India-based Serum Institute initiated a clinical trial in 2017 for verifying the efficacy of its VIS513 monoclonal antibody to treat dengue infections throughout the Indian subcontinent. The company holds exclusive licenses to the treatment for commercialization across all seven countries and has invested a sum of USD 5 million, which would yield an additional USD 34 million upon achievement of the set milestone.
Similarly, Sun Pharmaceutical Industries Ltd. has forged a partnership with the International Center for Genetic Engineering and Biotechnology (ICGEB) to develop a dengue vaccine that is safe, effective, and affordable. As per this agreement, Sun Pharma is funding and developing the DSV-4 vaccine candidate that targets all four serotypes of the dengue virus.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
As is established, the global dengue vaccines market is currently characterized by the presence of a single vaccine candidate, Sanofi Pasteur’s Dengvaxia®. Moreover, upcoming vaccine candidates are still undergoing phase II/III clinical trials, meaning that their market availability will be postponed.
Until that time, medical practitioners will have to rely on topical drug treatments. Additionally, basic sanitation and hygiene practices are the only course of action in some regions, as availing of the vaccine is often very expensive. All these factors are anticipated to decelerate the growth of the dengue vaccine market to a significant extent.
According to the Centers for Disease Control and Prevention (CDC), dengue outbreaks occasionally occur in the continental United States. However, these outbreaks are common across its overseas territories, including Puerto Rico, the United Sates Virgin Islands, and American Samoa respectively. On the mainland, outbreaks were frequent across Hawaii (2015), Florida (2013, 2020), and Texas (2013).
Between January 2010 and December 2017, a total of 5,387 dengue cases were reported. The majority of these were associated with travel (5,009; 93%), with the median patient age at 41 years. Over half of the cases (54%) were reported from five states: New York (18%), California (16%), Florida (14%), Texas (5%), and New Jersey (5%). This led to an overall hospitalization rate of 40%.
In May 2019, the United Sates Food & Drug Administration approved the use of Sanofi’s Dengvaxia® live attenuated vaccine which is administered as three separate injections in 9-through-16 year olds. In addition, existing trials for the ChimeriVaxTM Tetravalent Dengue Vaccine are expected to yield conclusive results in the future, paving the way for the entry of another potential vaccine candidate. United State has emerged as a leading market, accounted for over 16.5% of the total demand registered in 2022.
The World Mosquito Program has established that mosquito-borne diseases are a growing threat to local communities across Mexico. A series of large-scale dengue outbreaks have occurred in recent years, with infection rates further poised to surge by 40% in the next 5 decades. Consequently, government initiatives to promote an extensive vaccination campaign have increased in the past few years.
Growth is accelerating amid an alarming increase in the incidence of dengue fever in the previous decade. An NCBI study published in 2015 estimated that the regional burden of the disease amounted to about 139,000 (95%) symptomatic and 119 fatal annual dengue episodes on average (2010-11). The annual cost of vector control and surveillance amounted to USD 170 million.
Besides introducing vaccines, the government is investigating highly sustainable and naturally controlling solutions. An example of this is the breeding of Wolbachia bacteria laden mosquitos, which when mixed with wild mosquitoes have a reduced chance of spreading the dengue virus and thus control its spread.
The National Vector Borne Disease Control Program initiated by the National Health Mission has been playing a highly instrumental role in managing and controlling the spread of dengue fever in India. Significant strides have been made, with the burden reducing from nearly 100,000 cases in 2015 to just over 4500 as of March 2021.
While Sanofi’s Dengvaxia has dominated the Indian dengue vaccine market, in recent years, Takeda Pharmaceuticals has claimed progress in its vaccine efficacy up to 80% in a clinical trial conducted amongst 20,000 children aged between 4 and 16 years in the 12-month period after the second dose, which was administered three months after the first one.
While vaccine development is still in its nascent stages, efforts are ongoing to curb the disease’s spread by implementing a series of cleanliness and hygiene programs. For instance, in 2019, the Delhi government reported that there were over 200 Mohalla Clinics as opposed to 2015, which saw the very first clinic. These air conditioned private hospital-like atmosphere clinics distribute 109 essential medicines, and conduct 212 diagnostic tests run by a panel of highly competent doctors. The market in the India is projected to rise at a CAGR of 11.7% over the upcoming decades.
According to popular estimates, Brazil registers the highest number of global dengue cases, with 3.2 million active infections and 800 deaths reported from 2009 to 2014. This number increased by 600% in 2019. Lack of awareness regarding proper treatment and eradication is the key reason behind this massive upswing.
This problem is being further aggravated by the improvised expansion of cities, environmental destruction, and the unusually wet periods that have accompanied climate change. All of these changes are highly conducive to mosquito growth, thereby increasing the menace of this disease in recent years.
Hence, government initiatives to promote extensive vaccine deployment have increased. In December 2018, pharmaceutical giant Merck & Co. joined hands with the Instituto Butantan based in Sao Paulo to develop at least two vaccine candidates for this disease. The collaboration is backed by specific rights by the US National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) which has been developing the TV003 vaccine candidate.
By product, the CYD-TDV (Dengvaxia) shall continue dominating the dengue vaccines market, attributed to the fact that presently it is one of the only most widely available vaccine candidates to treat dengue infections worldwide. The CYD-TDV (Dengvaxia) vaccine is the first dengue vaccine to be licensed, beginning in 2015 in Mexico.
Presently, Dengvaxia is being marketed by pharmaceutical giant Sanofi Pasteur and has been approved across 19 countries and the European Union. It also gains approval across the US market in 2019. The vaccine is approximately 76% effective in preventing symptomatic, laboratory confirmed dengue diseases in 9 through 16 years of age. Simultaneously, several other corporations are developing new vaccine candidates, thus generating immense revenue potential.
By end-user, governments are anticipated account for the bulk of the global dengue vaccines market demand, generating over half of the total revenue share by 2033-end. This is largely attributed to the increasing number of policy level initiatives to reduce the incidence of dengue fever across major countries.
Over the years, major eradication campaigns have been initiated across emerging economies such as India, Brazil, Mexico, Malaysia, Vietnam, and several African nations, as these are considered to be key dengue hotspots. Consequently, clinical trials have been initiated by numerous pharmaceutical companies to augment vaccine availability, thus stimulating growth. The Government Institutes segment hold a market share of Government Institutes in 2022.
Conducting clinical trials to develop multiple vaccine candidates remains the core expansion strategy of the aforementioned manufacturers. To enable this, market players are effectively leveraging strategic partnerships with major pharmaceutical corporations or research institutes, mergers & acquisitions, and capacity expansion initiatives.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Dengue Vaccines Market Value (2023) | USD 474.8 million |
| Dengue Vaccines Market Expected Value (2033) | USD 1603.7 million |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD million for Value & ‘000 Units for Volume |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Covered | United States, Canada,, Brazil, Mexico, Germany, Italy, France, United Kingdom, Spain, China, Japan, South Korea, Singapore, Thailand, Indonesia, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Segments Covered | Product, End-User, Region |
| Key Companies Profiled | Sanofi Pasteur Limited; Takeda Pharmaceutical Company Limited; Merck & Co. Inc.; GlaxoSmithKline Plc.; GeneOne Life Science Inc.; Medigen Vaccine Biologics Corporation; Panacea Biotec Limited; Sun Pharmaceutical Industries Ltd; Serum Institute of India Pvt. Ltd.; Biological E Ltd. |
| Customization & Pricing | Available upon Request |
In 2023, the market is expected to be worth USD 474.8 million.
The market may continue to be dominated by the CYD-TDV (Dengvaxia).
The market is poised to endure at a 12.9% CAGR through 2033.
The global market is anticipated to be worth USD 1603.7 million by 2033.
Governments are expected to account for the majority of the market demand.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. CYD-TDV (Dengvaxia) 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 6.1. Hospitals 6.2. Government Institutes 6.3. Non-governmental Organizations (NGOs) 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. MEA 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. Sanofi Pasteur Limited 15.2. Takeda Pharmaceutical Company Limited 15.3. Merck & Co. Inc. 15.4. GlaxoSmithKline Plc. 15.5. GeneOne Life Science Inc. 15.6. Medigen Vaccine Biologics Corporation 15.7. Panacea Biotec Limited 15.8. Sun Pharmaceutical Industries Ltd 15.9. Serum Institute of India Pvt. Ltd. 15.10. Biological E Ltd. 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Dengue Vaccines Market
